overall cognition index (oci) score (CogState Ltd)
90
Structured Review
CogState Ltd
overall cognition index (oci) score
Overall Cognition Index (Oci) Score, supplied by CogState Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computerized+cognitive+testing+cogstate/overall+cognition+index++oci++from+the+cogstate+testing+battery/pmc04864641-90-8-7
Average 90 stars, based on 1 article reviews
Overall Cognition Index (Oci) Score, supplied by CogState Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computerized+cognitive+testing+cogstate/overall+cognition+index++oci++from+the+cogstate+testing+battery/pmc04864641-90-8-7
Average 90 stars, based on 1 article reviews
overall cognition index (oci) score - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Abstracts for the 15th International Congress on Schizophrenia Research (ICOSR) Article Snippet: The primary efficacy endpoint was the Overall Cognitive Index (OCI) score from the Article Title: The following abstracts were presented as posters at the 2014 NEI Psychopharmacology Congress Article Snippet: Efficacy was evaluated using the Overall Cognition Index (OCI) from the Article Title: Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α 7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia Article Snippet: The primary efficacy end point was the Article Title: Emerging drugs for schizophrenia: an update. Article Snippet: Introduction: Schizophrenia is one of the most serious mental disorders.. Its treatment remains challenging, as existing antipsychotic antidopaminergic medications improve only/predominantly positive symptoms, agitation and aggression but have limited/insignificant efficacy for negative and cognitive symptoms, which strongly affect functional outcome.. Therefore, new therapeutic agents are urgently needed that treat aspects of the spectrum of schizophrenia symptomatology and improve functional outcome. Article Title: Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? Article Snippet: Current therapeutics for schizophrenia, the typical and atypical antipsychotic class of drugs, derive their therapeutic benefit predominantly by antagonism of the dopamine D2 receptor subtype and have robust clinical benefit on positive symptoms of the disease with limited to no impact on negative symptoms and cognitive impairment.. Driven by these therapeutic limitations of current treatments and the recognition that transmitter systems beyond the dopaminergic system in particular glutamatergic transmission contribute to the etiology of schizophrenia significant recent efforts have focused on the discovery and development of novel treatments for schizophrenia with mechanisms of action that are distinct from current drugs.. Specifically, compounds selectively targeting the metabotropic glutamate receptor 2/3 subtype, phosphodiesterase subtype 10, glycine transporter subtype 1 and the alpha7 nicotinic acetylcholine receptor have been the subject of intense drug discovery and development efforts. Article Title: Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the ?7 Nicotinic Receptor Article Snippet: Efficacy was evaluated using the Overall Cognition Index (OCI) from the |
